Another irreversible pan-ErbB family TKI, dacomitinib, was not superior to erlotinib in an unselected, previously treated, advanced NSCLC patient population in the ARCHER 1009 study, whereas in the ARCHER 1050 trial, dacomitinib significantly improved PFS (14.7 months vs. 9.2 months) and OS (34.1 months vs. 26.8 months) over gefitinib in the first-line setting [8, 43, 44]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.